| Name | Thiodigalactoside |
| Description | Thiodigalactoside (TDG), a non-metabolizable disaccharide, serves as an orally active, potent galectin (GAL) inhibitor, exhibiting Kd values of 24 μM and 49 μM for GAL1 and GAL3, respectively. Demonstrating anti-inflammatory and anti-cancer properties, it significantly diminishes body weight gain in diet-induced obese rats. |
| In vitro | Thiodigalactoside (TDG; 250 and 500 μM) demonstrates a dose-dependent decrease in fat accumulation, as evidenced by reductions in triglyceride (TG) content and Oil Red O (ORO) staining[1]. |
| In vivo | Thiodigalactoside (TDG; 5 mg/kg; IP; once per week for 5 weeks) significantly inhibits HFD-induced body weight gain, whereas oral administration (5 mg/kg; daily or weekly for 5 weeks) provides less reduction in body weight gain compared to IP administration [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | PBS (pH 7.2) : 10 mg/mL (27.9 mM), Sonication is recommended. H2O : 90 mg/mL (251.14 mM), Sonication is recommended. DMF : 1 mg/mL (2.79 mM), Sonication is recommended. DMSO : 50 mg/mL (139.52 mM), Sonication is recommended.
|
| Keywords | Thiodigalactoside | Galectin |
| Inhibitors Related | G3-C12 acetate(848301-94-0 free base) | Galectin-3 antagonist 2 | SNAP 398299 | Galectin-3/galectin-8-IN-2 | Galectin-3/galectin-8-IN-1 | GB1107 | DB21, Galectin-1 Antagonist | OTX008 | TD139 |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Orally Active Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |